FDA Guidance Notes Monocyte Activation Test as a Suitable Replacement for the Rabbit Pyrogen Test
October 31, 2012 - Charles River is committed to expanding our portfolio within vitro alternatives to in vivo tests. In addition to the long-standing in vivo and in vitro (e.g., LAL) tests for the detection of pyrogens and endotoxins, Charles River offers the Monocyte Activation Test (MAT). The MAT is used to detect or quantify substances that activate human monocytes or monocytic cells to release endogenous mediators.
In a recent guidance document, the FDA indicated that alternative tests such as the MAT may be substituted for the Rabbit Pyrogen Test as long as “equivalent Pyrogen detection” can be demonstrated (Guidance for Industry, Pyrogen and Endotoxins Testing: Questions and Answers, June 2012). The MAT is also considered “suitable, after a product-specific validation, as a replacement for the Rabbit Pyrogen Test” according to the European Pharmacopoeia Monograph 04/2010:20630.
The MAT works by predicting the human response to pyrogens on the basis of human fever, rather than animal models. The MAT offered by Charles River detects (by ELISA) the release of the important inflammatory mediator IL-1β from cryopreserved human blood.
Charles River offers clients the opportunity to work closely with our team of experienced staff to develop the MAT for testing their products. Our staff will work with clients to first determine the suitability of the MAT for testing their products; GMP product-specific validations may then be conducted on suitable products prior to its use in release testing.
For more information, contact us at:
*indicates a required field.
The information you provided will be kept confidential.
We have established an in vivo screening platform to provide fast and cost-effective screening of compound effects on motor behavior and brain functionality for the study for central nervous system diseases.
We offer a package of well-established, state of the art in vitro mode of action assays that are suitable for early phase biocomparability studies, lot release and stability. These tests can accelerate the time it takes to get a new product ready for market submission.
May 28–Jun 01
The International Bone and Mineral Society (IBMS) and the Japanese Society for Bone and Mineral Research (JSBMR) are excited to sponsor the second joint scientific meeting by the two organizations.
May 27–May 29
Charles River and the René Remie Surgical Skills Centre (RRSSC) have joined their expertise and are pleased to offer a 3-day surgery training course. Held at the RRSSC in the Netherlands, this training is designed to be very practical and combines lectures with hands-on exercises, ensuring you receive the most comprehensive training experience. This course is recommended for simple procedures only (e.g., simple exeresis, simple catheterizations such as jugular vein or femoral vein, simple ALZET pump implantation, ECG radiotelemetry).
This position is responsible for serving as a as a study director (SD), project scientist (PS) and/or principal investigator (PI) in the direction and execution of assigned studies in compliance with GLP regulations as they apply to the conduct of nonclinical research; coordinating all phases of the study planning process with appropriate departments; generating high-quality project plans, protocols, amendments and reports appropriate for assigned studies; reviewing, interpreting, integrating and presenting data on assigned studies; and functioning as contact for the planning and execution of sponsor interaction related to assigned studies, including proposal management and study scheduling, conduct and reporting.
This position is responsible for managing international aspects of US Federal income tax compliance; assisting with international tax planning, including identification of planning opportunities, designing and implementing plans, and transfer pricing process; overseeing quarterly ETR forecast process; and participating in the tax provision process, including assessment of tax risks, documentation of key positions, and review of non-US tax provision submissions.
Charles River Laboratories, Inc.